Articles | Open Access | https://doi.org/10.55640/

THE NEW CLASS OF ANTIDIABETIC DRUGS: INCRETIN MIMETICS

Umarova Makhfuza Mirzakarimovna  ,  Faculty of Pharmacy, Department of Pharmaceutical Sciences, Andijan State Medical Institute, Uzbekistan

Abstract

Incretin mimetics represent a novel class of antidiabetic drugs that mimic the physiological actions of endogenous incretin hormones, primarily glucagon-like peptide-1 (GLP-1). These agents improve glycemic control through glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying, and appetite reduction. Compared to traditional therapies, incretin mimetics offer enhanced efficacy with a lower risk of hypoglycemia and potential benefits for weight management and cardiovascular protection. This article reviews their pharmacological mechanisms, therapeutic applications, safety profile, and clinical significance in the management of type 2 diabetes mellitus (T2DM).

Keywords

Incretin mimetics, GLP-1 receptor agonists, type 2 diabetes mellitus, semaglutide, liraglutide, glycemic control, pharmacotherapy

References

Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. 2018;27(4):740–756.

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2016;375(4):311–322.

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016;375(19):1834–1844.

Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2018;6(6):477–490.

Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503–515.

Drucker DJ. Advances in oral peptide therapeutics. Nature Reviews Drug Discovery. 2020;19(4):277–289.

Article Statistics

Downloads

Download data is not yet available.

Copyright License

Download Citations

How to Cite

THE NEW CLASS OF ANTIDIABETIC DRUGS: INCRETIN MIMETICS. (2025). International Journal of Medical Sciences, 5(10), 183-186. https://doi.org/10.55640/